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Objectives: This study aimed to determine the cellular distribution of
islet cannabinoid receptors (CBs) and their involvement in the devel-
opment of metabolic and hormonal changes in rats fed a fructose-rich
diet (F).
Methods: In normal rat islets, we determined CBs (immunofluores-
cence and retrotranscriptionYpolymerase chain reaction) and glucose-
stimulated insulin secretion (GSIS) of isolated islets incubated with the
CB1 antagonist rimonabant (R) and/or different CBs agonists. In 3-week
F-fed rats, we determined the in vivo effect of R on serum glucose, tri-
glyceride, and insulin levels; homeostasis model assessment for insulin
resistance, GSIS, and CBs and insulin receptor substrate gene expression
levels (real-time polymerase chain reaction).
Results: Cannabinoid receptors appeared exclusively in islet > cells.
Whereas different CB agonists enhanced GSIS in normal rat islets, R did
not affect it. F rats had higher serum triglyceride and insulin levels and
homeostasis model assessment for insulin resistance than control rats;
these alterations were prevented by R coadministration. Although R did
not correct the increased GSIS observed in F islets, it modulated CBs
and insulin receptor substrate gene expression.
Conclusions: Islet CBs would exert an important modulatory role in
metabolic homeostasis. Administration of R and F affected islet CB
expression and prevented the development of F-induced metabolic im-
pairment. Selective islet CB1 blockers could be useful to prevent/treat
the alterations induced by the intake of unbalanced/unhealthy diets.
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The endocannabinoid system comprises 2 cannabinoid recep-tor (CB) subtypes, CB1 and CB2, with specific endogenous
ligands (anandamide [AEA] and 2-arachidonoylglycerol) as well
as specific enzymes for ligand biosynthesis and degradation,
that is, sn-1-selective diacylglycerol lipase->, monoacylglycerol
lipase, N-arachidonoyl phosphatidyl ethanolamine phospholipase
D, and fatty acid amide hydrolase.1
It has been claimed that these receptors actively partici-
pate in the control of energy homeostasis,2,3 an assumption
supported by the transient reduction of food intake induced by
the administration of a CB1 blocker, rimonabant (R), to either
food-deprived lean or ad libitum-fed obese animals.3Y5 Further,
published evidence strongly suggests that the endocannabinoid
system exerts a tonic modulation on appetite and other metabolic
functions.3Y5 In this sense, other reported data support this con-
cept, namely, (a) the persistent weight loss induced by chronic
CB1 blockade is independent from food intake inhibition6,7 and
(b) CB1-deficient mice have significantly less fat mass than wild-
type mice and are not susceptible to develop obesity when fed
with a high-fat diet.8 Altogether, these findings suggest that the
endocannabinoid system contributes positively to obesity devel-
opment, probably via the up-regulation of liver receptors, as
shown in mice with dietary-induced obesity.9
Obesity is accompanied by a decrease in insulin sensitivity
and a compensatory increase in A-cell function/mass, with the
consequent increase in serum insulin levels.10 At early stages, a
modest increase in serum glucose levels within reference range
can also be observed11; at later stages and in people at risk, this
situation leads to the development of overt type 2 diabetes
(T2DM).12 It is clear that obesity represents an overload of the
A-cell function and contributes to its failure in subjects with
genetic predisposition.13 On the other hand, it is accepted that
CB1 and CB2 are present in pancreatic islets, despite some
controversies about their cellular distribution and their effect
on insulin and glucagon secretion.14Y25 Conversely, the poten-
tial role of such receptors in the cross-talk between obesity
(adipose tissue) and A-cell function in normal and pathological
conditions is not completely clear as yet.
Administration of high sucrose or fructose (F) diets to nor-
mal rats induces early hormonal and metabolic changes that re-
semble the human prediabetes, diabetes, and metabolic syndrome
profiles, that is, high serum insulin and triglyceride levels, in-
sulin resistance (IR), impaired glucose tolerance, increased
abdominal adipose tissue with impaired adipokine release, and
decreasedA-cell mass ascribed to an increased apoptosis rate.26Y30
Consequently, F might be a suitable model to answer the previ-
ously mentioned question.
In an attempt to obtain new evidence of the possible role of
the cannabinoid system in the regulation of the A-cell secretory
function and metabolic homeostasis, we studied the effect of F
and R coadministration to normal rats for 3 weeks. Our findings
demonstrate that (a) R administration prevents the development
of multiple F-induced hormonal and metabolic disturbances,
including hyperinsulinemia, and (b) in isolated pancreatic islets,
the characterized functional CBs would play an active role in
the mechanism by which R exerts such effect.
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MATERIALS AND METHODS
Chemicals and Drugs
Collagenase was obtained from Serva Feinbiochemica
(Heidelberg, Germany); bovine serum albumin (BSA) fraction
V, AEA, arachidonyl-2-chloroethylamide (ACEA), JWH-015,
and other reagents were from Sigma Chemical Co (St Louis,
Mo); R was from Sanofi-Aventis and F was obtained from Corn
Products International Inc (Westchester, Ill).
Experimental Animals
Normal adult male Wistar rats (180Y200 g bw) were kept
in a temperature-controlled environment (23-C) on a fixed 12-hour
light/dark cycle and fed ad libitum for 1 week (stabilization period)
with a standard commercial diet (rat chow, Ganave; Argentina).
This study protocol complies with the NIH guide for the care and
use of laboratory animals (National Research Council, 1985).
CB1 and CB2 Immunohistochemical Detection
in Normal Rat Pancreases
Normal rats were anesthetized and perfused with 4%
paraformaldehyde in phosphate buffer. Pancreases were care-
fully dissected and cryopreserved in graded sucrose solutions
and a sucrose-OCT compound mixture. Tissue blocks were
frozen in N2-cooled acetone and sectioned at 7 Km.
Cryosections were incubated with dilutions of our own
guinea pig insulin antibody, rabbit anti-glucagon (kindly pro-
vided by Novo Nordisk, Copenhagen, Denmark), and/or anti-
somatostatin antibody (a gift from Dr S. Efendic, Department
of Endocrinology, Karolinska Institute, Stockholm, Sweden).
CB1 was detected with 2 specific antibodies, OPA1-15297
(1:500; Affinity BioReagents, Golden, Co) when immunofluo-
rescence was performed in triple combination with either insulin
and glucagon or insulin and somatostatin, and p-CB1 (Ser 316):
sc-17555 (1:50; Santa Cruz Biotechnology, Inc) in combination
with insulin. Two different CB2 antibodies were used to detect
CB2: PA1-746A CB2 (1:1000; Affinity BioReagents) in combi-
nation with either glucagon or somatostatin, and CB2 (M-15): sc-
10076 (1:50; Santa Cruz Biotechnology, Inc) in combination
with insulin.23 The reaction was completed by incubation with
anti-rabbit, -mouse, or -guinea pig antibodies conjugated with
fluorescein isothiocyanate, lissamine rhodamine or Cy5 (Jackson
Immunoresearch Laboratories, West Grove, Pa).
Confocal images were obtained with a Laser Scanning
System Radiance 2000 (BioRad, Hemel Hempstead, UK) and a
Confocal LEICA TCS SP5 AOBS microscope from the Na-
tional University of La Plata Microscopy Platform. The 488 line
of an argon laser, the 543 line of a helium-neon laser, and the
633-nm line from a diode laser were sequentially used. Cyto-
plasmic colocalization was evaluated in 1-Km-thick optical
sections. Optic projections and merged images were produced
with Confocal Assistant Software (BioRad). In all cases, images
were obtained from 3 pancreases and at least 3 sections from
3 different levels of the block. Control samples omitting incu-
bation with primary antibodies were run in parallel for every
immunostaining procedure tested.
Glucose-Stimulated Insulin Secretion, Islet
Insulin, and DNA Content
Pancreases from normal animals were removed to isolate
islets by collagenase digestion.31 Groups of 5 islets with similar
shape and size were incubated for 60 minutes at 37-C in 0.6 mL
Krebs-Ringer bicarbonate buffer, pH 7.4, previously gassed
with a mixture of CO2/O2 (5%/95%), containing 1.5% (wt/vol)
BSA and 3.3 or 16.7 mM glucose for glucose-stimulated
insulin secretion (GSIS) determination. Under these condi-
tions, we tested separately the effect of the endocannabinoid
AEA (Sigma-Aldrich, 1Y200 KM), of 2 different specific CB
agonists: the specific CB1 agonist ACEA (0.1Y20 KM, Sigma-
Aldrich) and the specific CB2 ligand JWH-015 (CB2 agonist,
Sigma-Aldrich, 0.1Y20 KM), and R (CB1 antagonist, Sanofi-
Aventis, France, 0.01Y1 KM). We also studied the effect of
the combination of R and AEA or ACEA. Because all these
compounds were dissolved in DMSO, its concentration was
kept identical in each condition/tube tested (final DMSO
concentration 1:1000). At the end of the incubation period,
aliquots from the medium were taken and kept frozen for in-
sulin assay,32 whereas the islets were suspended in water and
immediately sonicated to extract and measure their insulin con-
tent by radioimmunoassay (RIA).32 The amount of DNA per islet
was also measured to express GSIS as a function of its content.
Total RNA Isolation, Retrotranscription, and
Polymerase Chain Reaction
After killing, the brain, spleen, and pancreas from normal
animals were removed. Total RNA was obtained from isolated
rat islets, brain, and spleen using TRIzol Reagent (Gibco-BRL,
Rockville, Md) following the manufacturer’s instructions. The
integrity of the isolated RNA was checked by 1% agarose-
formaldehyde gel electrophoresis. Possible contamination with
protein or phenol was controlled by measuring the 260/280-nm
absorbance ratio, whereas DNA contamination was avoided
using 1 U/KL DNAase I (Gibco-BRL).
Retrotranscription (RT) reaction was performed using
200 U/KL Super Script III reverse transcription (Gibco-BRL),
oligo dT (Invitrogen), and 1-Kg total RNA as template. Nega-
tive controls were performed by omission of SuperScript III in
the reaction mix.
For polymerase chain reaction (PCR), specific primers based
on the rat CB1 and CB2 complementary DNA (cDNA) sequences
were used: sequence 5¶ to 3¶, forward primer (A) and reverse
primer (B): CB1 (NM_012784.3): A, ttccgtaccatcaccacaga; B, agtg
caggatgacacacagc; product size, 397 bp. CB2 (AF218846.1): A,
atctttgcctgcaacttcgt; B, acatgttggtgtgctttcca; product size, 404 bp.
A-Actin primers were used as a positive control of the PCR
(V01217: A, cgtaaagacctctatgccaa; B, agccatgccaaatgtctcat, prod-
uct size, 473 bp).
Polymerase chain reactions were run using 1/40th of the
cDNA or negative control as template, 1 Kmol/L forward and
reverse primers, 40 mU/KL Platinum Taq DNA polymerase
(Invitrogen), 3 mM MgCl2 and 0.2 mM dNTPs. The cycling pro-
file was as follows: a first step of 2 minutes at 94-C followed by
35 cycles of 30 seconds at 94-C, 1 minute at 60-C, and 1.5 minutes
at 72-C with a final step of 10 minutes at 72-C. Polymerase
chain reaction products were separated by electrophoresis on a
2% (wt/vol) agarose gel and stained with ethidium bromide.
In Vivo Studies
Normal rats were randomly divided into 3 groups (n = 12
each group) and received the following diets during 21 days: a
powdered standard commercial diet and tap water ad libitum
(control, C); the same diet as C plus 10% (wt/vol) fructose in the
drinking water (F); the same diet as F plus 105 mg R per kg of
food powder (R-F; under our conditions, this concentration as-
sures a mean R intake of 2 mg/rat per day). Body weight together
with food and water intake were checked every second day.
Blood Measurements and GSIS
Blood samples were drawn from the retroorbital plexus of
nonfasted animals at the time of killing (around 9:00 A.M.) under
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light isofluorane (1-chloro-2,2,2-trifluoroethyl difluoromethyl
ether; Abbott, Ill) anesthesia to measure serum glucose, insulin,
and triglyceride levels. Thereafter, animals were killed by cervi-
cal dislocation.
Glucose levels were measured in each animal using the Accu-
Check Performa glucometer (Roche Diagnostics, Germany). Tri-
glyceride levels were assessed with enzymatic commercial kits
(Bayer Diagnostics, Argentina) implemented in an automated
clinical analyzer. Insulin levels were determined by RIA using rat
insulin standard.32 Insulin resistance and the A-cell reserve were
assessed with the homeostasis model assessment for IR (HOMA-
IR) and the HOMA for A-cell function (HOMA-A) scores, re-
spectively, calculated with the formula described by Matthews and
coworkers.33
Glucose-stimulated insulin secretion was performed in
islets isolated from all experimental groups31 and incubated
for 60 minutes in the presence of different glucose concen-
trations (3.3, 8.0, and 16.7 mM). Insulin released to the incu-
bation media was determined by RIA32 as described before.
Insulin release was thereafter expressed as ng per Kg of DNA
in 1 hour (ng/Kg DNA per hour).
Analysis of Islet Gene Expression
by Real-Time PCR
cDNA of islets isolated from each study group was obtained as
described before. Real-time PCR (qPCR) was performed with a
Mini Opticon Real-Time PCR Detector Separate MJR (BioRad),
using SYBR Green I as a fluorescent dye and 1/40th of the islet
cDNA as template. Reactions were performed in a 25-KL qPCR
reaction mixture containing 0.36 KM of each primer, 3 mMMgCl2,
0.2 mM dNTPs, and 40 mU/KL Platinum Taq DNA polymerase
(Invitrogen). Polymerase chain reaction profile was as follows: a first
step of 3 minutes at 95-C followed by 40 cycles of 30 seconds at
95-C, 30 seconds at 65-C, and 45 seconds at 72-C, with a final
extension step of 10 minutes at 72-C followed by a melting
curve from 55-C to 90-C. The optimal parameters for the PCR
reactions were empirically defined. Each PCR amplification was
performed in triplicate. The oligonucleotide primers (Invitrogen) used
were as follows: sequence 5¶ to 3¶, forward primer (A) and reverse
primer (B): CB1 (NM_012784.3): A, cgtaaagacagccccaatgt and B,
tacctgtcgatggctgtgag; CB2 (AF218846.1): A, cctgttgaagatcggcagcg
and B, ggtaggagatcaacgccgag; insulin receptor substrate 1 (IRS1,
NM_012969.1), A, tgtgccaagcaacaagaaag and B, acggtttcaga
gcagaggaa; IRS2 (NM_001168633.1): A, ctacccactgagcccaagag
and B, ccagggatgaagcaggacta. All amplicons were in a size
range of 90 to 250 bp. A-Actin (V01217) was used as house-
keeping gene (primer sequences: A, agagggaaatcgtgcgtgac and B,
cgatagtgatgacctgaccgt). The purity and specificity of the am-
plified PCR products were verified by performing melting
curves and were further checked by 2% (wt/vol) agarose gel
FIGURE 1. Cannabinoid receptor expression in normal rat tissues
(RT-PCR). Lanes 1 and 2, normal rat brain; lane 1, CB1; lane 2,
A-actin. Lanes 3Y6, normal rat islets; lane 3, CB1; lane 4,
RT-negative control; lane 5, CB2; lane 6, A-actin. Lanes 7 and 8,
normal rat spleen; lane 7, CB2; lane 8, A-actin. MW indicates
molecular weight marker. Polymerase chain reaction product
sizes: CB1, 397 bp; CB2, 404 bp; A-actin, 473 bp.
FIGURE 2. CB1 identification in islet cells. Confocal optical
sections (1 Km) showing cellular CB1 localization in rat islets.
A, Left panels show the same section immunostained for CB1
(green), glucagon (Glu, red) and insulin (Ins, blue). In the right
panel, the 3 images were merged, demonstrating the presence
of CB1 in > cells. B, Left panels show the same section
immunostained for CB1 (green), somatostatin (Som, red), and
insulin (Ins, blue). The merged image on the right shows the lack
of CB1 colocalization with somatostatin or insulin. C, Double
immunofluorescent labeling of CB1 (red) and insulin (Ins,
green), demonstrating the peripheral distribution of CB1
immunoreactive-positive cells. In all cases, images are
representative of 3 pancreases and at least 3 sections from
3 different levels of the block, calibration bar equals 20 Km.
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electrophoresis and ethidium bromide staining. Data are
expressed as relative gene expression respect to control group
after normalization to the A-actin housekeeping gene, by
using the C-C Ct method.
Statistical Analysis
The statistical analysis was performed using 1-way analy-
sis of variance followed by Bonferroni t test considering dif-
ferences as significant when P was less than 0.05.
RESULTS
Islet Expression and Cellular Distribution of CB1
and CB2 in Normal Rats
RetrotranscriptionYpolymerase chain reaction (RT-PCR)
demonstrated the expression of CB1 and CB2 genes in islets
isolated from normal rat pancreases (Fig. 1). The brain and
spleen cDNA was used as positive control. The immunohisto-
chemical identification showed that CBs were always present in
the periphery of the islets (Figs. 2 and 3). Whereas double and
triple immunofluorescent labeling revealed CB1 (Fig. 2) and
CB2 (Fig. 3) colocalization in glucagon-producing cells, they
were not detected in somatostatin- or insulin-producing cells.
Direct Effect of AEA, ACEA, JWH-015, and R on
GSIS In Vitro
In all cases, islets isolated from normal rats were chal-
lenged with low (3.3 mM) and high (16.7 mM) glucose and
insulin was expressed as the increase of the latter above low
glucose (Fig. 4). Addition of AEA or either the specific CB1
(ACEA) or CB2 (JWH-015) agonists to the incubation media
did not affect insulin release in response to a low glucose con-
centration (data not shown). Conversely, all these agents sig-
nificantly affected insulin secretion unevenly in response to
16.7 mM glucose (Fig. 4A), whereas AEA enhanced it in a
dose-response fashion (P G 0.05 at 100 and 200 KM concen-
tration), both CB agonists tested showed a significant en-
hancement at 1 KM (P G 0.05), followed by a decrease at higher
concentrations (P G 0.05 at 20 KM).
No significant changes in insulin secretion were recorded
when the islets were incubated with different R concentrations;
however, the simultaneous addition of R and stimulatory con-
centrations of either AEA or ACEA to the incubation media
significantly decreased the amount of insulin released in re-
sponse to 16.7 mM glucose (P G 0.05, Fig. 4B).
In all the experimental groups, insulin content in the islets
after GSIS was significantly higher in islets incubated with
3.3 mM glucose as compared to those challenged with 16.7 mM
glucose (P G 0.05, not shown). On the other hand, no differ-
ences were recorded in insulin content when comparing groups
incubated with the same glucose concentration.
FIGURE 3. CB2 identification in islet cells. Confocal optical
sections (1 Km) showing CB2 localization in rat islets. A, Left
panels show the same section immunostained for CB2 (green)
and glucagon (Glu, red). The merged image on the right shows
complete colocalization of CB2 and glucagon signals, indicating
the presence of this receptor in >-cells. B, Left panels show the
same section immunostained for CB2 (green) and somatostatin
(Som, red). The merged image on the right demonstrates the
lack of CB2 colocalization with somatostatin. C, Left panels show
the same section immunostained for CB2 (red) and insulin
(Ins, green). On the right panel, merged images show the lack of
CB2 colocalization with insulin. D, The same islet as in panel C
labeled with CB2 (red) and insulin (green) shows all CB2 positive
cells located in the periphery of the islets. In all cases, images are
representative of 3 pancreases and at least 3 sections from
3 different levels of the block, calibration bar equals 20 Km.
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Effect of R and F Coadministration on Body
Weight and Metabolic Parameters
F-fed rats significantly increased energy and water intake,
body weight as well as serum insulin and triglyceride levels as
compared to C (P G 0.05; Tables 1 and 2). These changes were
accompanied by a significant increase in the HOMA-IR index
(P G 0.05), thus demonstrating the presence of an IR state in
these rats. No significant changes in the HOMA-A index were
detected among the experimental groups.
Coadministration of F and R significantly decreased the
daily food intake (P G 0.05); this effect was accompanied by the
disappearance of F-induced changes in serum triglyceride and
insulin levels, as well as by a significant decrease in the
HOMA-IR index (P G 0.05).
Effect of R on CB1 and CB2 Gene Expression
Islets from F rats showed a higher CB1 mRNA level (P G
0.05) than those from C, whereas CB2 mRNA level did not
change after F administration (Fig. 5). CB1 blockage by R in-
duced a significant CB2 increase in F rats (P G 0.05) and did not
modify the F-induced changes recorded in CB1 gene expression
(the increment found in R-F with respect to F islets was not
significant).
Effect of R on GSIS and IRS Gene Expression
Islets isolated from F rats released significantly more in-
sulin than those from C ones in response to 8.0 and 16.7 mM
glucose (P G 0.05; Fig. 6), whereas administration of R to F rats
did not affect the changes observed in GSIS (Fig. 6).
F unevenly modified the expression levels of IRS genes
(Fig. 7), decreasing significantly IRS1 (P G 0.05) and in-
creasing IRS2 (P G 0.05) mRNA levels with respect to C. As
shown in Figure 7, coadministration of R and F recovered IRS1
gene expression level (F vs R-F, P G 0.05), but failed to fully
correct the changes observed in IRS2 mRNA level: it decreased
with reference to F (NS), but was still higher than in C islets
(P G 0.05).
DISCUSSION
It is well known that several components of the endo-
cannabinoid system are present in islet cells. In fact, Li et al34 have
recently shown that endocannabinoid 2-arachidonoylglycerol and
monoacylglycerol lipase, the enzyme that catalyzes its degradation,
are involved in the regulation of islet function.34 Great efforts have
been made in the last 10 years to understand the presence, cell
distribution, and role of islet CBs in the control of A-cell function
and glucose homeostasis. Different CB1 and CB2 localizations in
islet cells have been reported, depending on the species or cell line
used. In rat and mouse islets, CB1 has been identified in non-A
cells,14,15 in either > and C cells,16Y18 or specifically in glucagon
producing > cells,19 whereas its presence in C18 and A cells20,21 has
been reported in human islets. Our findings confirm the presence
of CB1 in > cells but not in other rat islet cells. Because previous
confocal colocalization studies did not report the use of single
(1 Km) optical sections, the presence of a minor proportion of
A cells displaying CB1 might be rather artifactual.
FIGURE 4. Insulin released by islets isolated from normal rats
challenged with 16.7 mM glucose. A, Islets incubated in the
presence of vehicle (1:1000 DMSO, Control [C] white column),
1Y200 KM AEA, 0.1Y20 KM ACEA, and 0.1Y20 KM JWH-015.
*P G 0.05 compared to C. B Islets incubated in the presence of
vehicle (1:1000 DMSO), 100 KM AEA, or 1 KM ACEA combined
with 0Y1 KM R. *, §, and ^ P G 0.05 compared to C (white
column), 100 KMAEA without R (light gray bar) and 1 KM ACEA
without R (gray column), respectively. In all cases, values were
calculated as ng of insulin released per Kg of islet DNA in
1 hour (ng/Kg DNA per hour). Values are expressed in arbitrary
units (AU) with respect to the amount of insulin released by the
islets exposed to 3.3 mM glucose (n = 15 in all cases).









C 2.27 (0.57) 20.4 (0.5) 24.6 (0.8) 59.1 (1.5)
F 3.43 (0.45)* 20.9 (0.7) 64.6 (9.1)* 86.2 (1.8)*
R-F 2.30 (0.52)† 15.8 (1.1)† 36.3 (5.1)† 60.1 (3.5)†
Values represent means (SEM) of the parameters recorded in 12 animals from each experimental group. P G 0.05 *compared to C, †compared to F.
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CB2 localization was more disputable: in islet cell sus-
pensions, they appeared in A and non-A cells,14,15 whereas in
intact islets a small CB2 immunoreactivity in somatostatin
(C)-17, glucagon (>)- and insulin-producing cells19 has been
reported. Conversely, other authors failed to demonstrate their
presence using either immunohistochemistry or RT-PCR16
techniques. Our results demonstrate the presence of CB2
mRNA and its immunocytochemical localization in non-A cells,
as reported by Starowicz et al.19 Although at present we cannot
exclude the presence of CB2 in C cells, our findings suggest
that if that were the case, they would only represent a minor
subpopulation.
Our data show that the endogenous cannabinoid AEA en-
hances GSIS in vitro in normal rat islets, and that different CB1
and CB2 agonists (at appropriate concentrations) also exert such
effect. These results lend support to similar results previously
reported in a rat insulinoma cell line,20 in fasting rats,23 and in
either perifused mouse islets24 or Min6 cells.25 Further, the in-
hibition of insulin secretion currently recorded at high concen-
trations of CBs agonists could explain earlier reports14Y19
showing that cannabinoids inhibit the hormone’s secretion.
A recent publication shows that islets isolated from nor-
mal rats and incubated with R did not change their response to
low glucose, but significantly decreased the one elicited by
high glucose.35 Under our experimental conditions, addition
of R to the incubation media did not cause any significant
effect on insulin secretion, thus suggesting the lack of a direct
effect on this process. However, when R was simultaneously
added with stimulatory concentrations of CB1 ligands (either
AEA or ACEA) to the incubation media, not only did they
abolish their GSIS enhancing effect, but it also decreased
insulin secretion, thus suggesting that the effect could be
mediated by islet CB1. Taken together, our results suggest that
even when CB1 are present and can modulate GSIS, they do
not exert a tonic effect on such process, at least under the ex-
perimental condition tested.
On the basis of the presence and cellular distribution of
CB1 and CB2 in non-A cells, we may assume that the effect of
these receptor agonists on insulin release depends on some type
of paracrine A- and >-cell interaction. This assumption is
supported by the early report of Pipeleers et al36 showing that
the potent insulin-releasing action of glucose in intact islets not
only depends on its fuel capacity but also on the concurrent
cAMP levels in A cells that were probably modulated by en-
dogenously released glucagon. The existence of a potential
tonic effect of the cannabinoid system on glucagon secretion
remains to be demonstrated.
There is clear evidence for an overactivity of the endo-
cannabinoid system during conditions of disrupted energy ho-
meostasis (eg, obesity and hyperglycemia) and for its active role
in the pathogenesis of the metabolic disorders present under
those conditions.2,3 In animals fed a high-fat diet, this overac-
tivity occurs simultaneously at central (hypothalamus) and pe-
ripheral (liver, pancreas, and adipose tissue) level.19 In this
regard, it has been previously shown that F administration to
normal rats induces a state characterized by high serum triglyc-
eride,37 insulin and leptin30 levels, high HOMA-IR index,26Y30,37
impaired glucose tolerance, abnormal fat29 and liver27 metabo-
lism, and a significant increase of glucoxidative markers,28 char-
acteristics that resemble those present in human diabetes and
metabolic syndrome.38 Administration of the CB1 blocker R to
these animals prevented the development of most of these
metabolic abnormalities and would, consequently, protect sensi-
tive tissues, such as pancreatic A cells,39 against the deleterious
FIGURE 5. mRNA levels of CB1 and CB2 determined by qPCR
in islets isolated from C, F, and R-F rats. Values are expressed in
AU relative to C and represent the mean of 3 independent
experiments. *Compared to C and §compared to F; in all cases,
P G 0.05.
TABLE 2. Serum Metabolites, Insulin Concentration, and HOMA Scores
Glucose, mmol/L Insulin, KU/mL Triglyceride, mg/dL HOMA-IR HOMA-A
C 5.04 (0.13) 10.54 (0.81) 56.0 (5.3) 2.34 (0.15) 159.6 (28.7)
F 5.53 (0.15) 15.88 (0.91)* 73.7 (3.5)* 3.90 (0.24)* 165.0 (16.5)
R-F 5.21 (0.34) 11.12 (0.95)† 63.7 (1.6)† 2.63 (0.28)† 174.5 (49.5)
Values represent means (SEM) of the parameters recorded in 12 animals from each experimental group. P G 0.05 *compared to C, †compared to F.
FIGURE 6. GSIS. Insulin released by islets isolated from C, F, and
R-F rats in response to different glucose concentrations
(3.3, 8.0, and 16.7 mM). Values are expressed as ng of insulin
released per Kg of DNA in 1 hour (ng/Kg DNA per hour). In all
cases, P G 0.05 for 3.3 mM compared to 8.0 mM and 16.7 mM
glucose and *compared to C (n = 15 in all cases).
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effect of lipotoxicity and IR,40 further preventing the increased
triglyceride accumulation in liver.41 R coadministration to F rats
also prevented the significant decrease recorded in islet IRS1
expression, whose active positive role in the control of A-cell
function42Y44 would help to understand how islet CBs modulate
such function and participate in overall metabolic homeostasis.
Although the beneficial effects of R on IR,45 lipid metab-
olism46 and metabolic lipid abnormalities present in people with
obesity47 have been previously reported, our results would be
the first to demonstrate a preventive effect of this compound.
The participation of islet CBs in the preventive effect of R is
also supported by the changes recorded in their expression at
islet level. In fact, as seen in obesity48 and diabetes,49 we ob-
served a significant increase in CB1 expression in F rat islets,
and the apparent discrepancy represented by the further increase
after R coadministration might only represent an attempt to
overcome CB1 blockade. The simultaneous change recorded in
CB2 expression would just reinforce the possible overall in-
volvement of the islet cannabinoid system in the pathogenesis
of F-induced metabolic dysfunction and its important role on
islet gene expression.23
In a recent publication, Vilches-Flores et al50 did not find
substantial changes in islet function when normal mouse islets
were treated in vitro with CBs agonists for up to 7 days; ac-
cordingly, they concluded that the effect of an overactivation of
the endocannabinoid system should act on IR rather than di-
rectly on A-cell function.50 Supporting this assumption, our
in vivo study demonstrated that R coadministration with F
prevented the diet-induced IR but did not improve GSIS.
Despite we have ascribed the preventive effect of R on
F-induced abnormalities to its blocking activity on CB1, we
cannot discard that some of these abnormalities might also
depend on its reported interaction with orphan G-coupled re-
ceptor (GPR55).51,52
In brief, our results show that (a) in normal rats, CB1 and
CB2 are present in the islets with a clear cell distribution, and in
intact animals, they would exert an important modulatory role
in metabolic homeostasis, (b) such role can be seriously affected
by administration of unbalanced diets (F in our case), and CBs
would thus participate in the pathogenesis of impaired meta-
bolic homeostasis, and (c) in that situation, administration of
a CB1 blocker was an effective preventive alternative. Because
R is not used any longer in clinics due to its off target effects,
the development of selective blockers directed to islet CB1 could
be a useful tool to prevent/treat the hormonal and metabolic al-
terations induced by the intake of unbalanced/unhealthy diets.
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